Karma Oncology

Executive Summary

Karma Oncology is a UK-based clinical development services company founded in 2018 that specializes exclusively in oncology. The company provides bespoke, flexible services to small and emerging biotech firms, offering pre-clinical consulting and end-to-end clinical trial execution. Operating with a virtual global team model, Karma Oncology delivers expertise in regulatory strategy, study design, and project management. As a private, pre-clinical stage company, it differentiates itself by tailoring its services to the specific needs of oncology drug developers, enabling clients to accelerate their programs while managing costs. With no disclosed funding rounds or valuation, Karma Oncology remains a niche player in the contract research organization (CRO) space, leveraging its specialized focus and agile approach to compete against larger, full-service CROs.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major Strategic Partnership with a Biotech40% success
• Q2 2026Launch of Novel Digital Platform for Trial Management50% success
• Q4 2026Expansion into US Market with First Client Win30% success